Showing 1481-1490 of 1644 results for "".
- Study Results Support Rapid Blood Pressure Reduction After Spontaneous Intracerebral Hemorrhagehttps://practicalneurology.com/news/results-of-a-secondary-analysis-support-intensive-blood-pressure-reduction-to-140-mmhg-after-spontaneous-intracerebral-hemorrhage/2474074/Findings from a secondary analysis of data from the phase 3 ATACH-II clinical trial (NCT01176565) suggest that intensive systolic blood pressure (BP) reduction to below 140 mmHg within 90 minutes of randomization is associated with decreased risk of hematoma expansion (HE) for people with spontan
- Substantially Higher Mortality Risk Demonstrated for Children and Adolescents with Severe Epilepsy and Sleep Apneahttps://practicalneurology.com/news/substantially-higher-mortality-risk-demonstrated-for-children-and-adolescents-with-severe-epilepsy-and-sleep-apnea/2474009/Study results presented at the American Academy of Neurology (AAN) 2025 Annual Meeting demonstrate that central sleep apnea (CSA) and other sleep apnea, including obstructive sleep apnea (OSA), are associated with an increased risk of mortality in children and adolescents aged 1 to 17 years with
- Data Regarding Novel CD40 Ligand Inhibitor as Potential Treatment for Individuals with Relapsing MS Presented at AAN 2025https://practicalneurology.com/news/data-regarding-novel-cd40-ligand-inhibitor-as-potential-treatment-for-individuals-with-relapsing-ms-presented-at-aan-2025/2474004/Results from an open-label extension (OLE) of a phase 2 clinical trial (NCT04879628) for frexalimab (Sanofi; Bridgewater, NJ), an investigational CD40 ligand inhibitor not associated with lymphocyte depletion being studied as a potential treatment for people with relapsing multiple sclerosis, wer
- Norepinephrine Reuptake Inhibitor Treatment Significantly Reduced Cataplexy Attacks in People with Narcolepsy Type 1https://practicalneurology.com/news/nri-therapy-significantly-reduced-cataplexy-attacks-in-people-with-narcolepsy-type-1/2473965/Treatment with AXS-12 (reboxetine; Axsome, New York, NY), a highly selective norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator, was associated with significant reductions in cataplexy attacks in people with narcolepsy type 1 (NT1), according to results from the phase 3 SYMPH
- Stem Cell Therapy Reduced Brain Atrophy in People with Mild Alzheimer Diseasehttps://practicalneurology.com/news/stem-cell-therapy-reduced-brain-atrophy-in-people-with-mild-alzheimer-disease/2473818/The intravenous (IV) treatment of people with mild Alzheimer disease (AD) using Lomecel-B (laromestrocel; Longeveron, Miami, FL), a bone-marrow–derived allogeneic mesenchymal stem cell (MSC), was associated with reduced atrophy of the whole brain and hippocampus compared with placebo. These
- Research Leaders Recognized at the 2025 MDA Clinical & Scientific Conferencehttps://practicalneurology.com/news/research-leaders-recognized-at-the-2025-mda-clinical-scientific-conference/2473814/The Muscular Dystrophy Association (MDA) recognized 2 legacy award recipients at the 2025 MDA Clinical & Scientific Conference. The awardees were honored based on their significant contributions to clinical research and community advocacy. The 2025 MDA Legacy Award for Achie
- Diagnosis and Care Recommendations for Limb-Girdle Muscle Dystrophy 2I/R9 Presentedhttps://practicalneurology.com/news/diagnosis-and-care-recommendations-for-limb-girdle-muscle-dystrophy-2ir9-presented/2473813/Draft standard of care (SoC) guidelines for the diagnosis and management of people with limb-girdle muscle dystrophy 2I/R9 (LGMDR9) were presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. According to the presenters of the draft SoC, the guidelines ar
- Gene Therapy Shown to Improve Motor Ability for Children with SMAhttps://practicalneurology.com/news/gene-therapy-shown-to-improve-motor-ability-for-children-with-sma/2473812/Treatment with OAV101 IT (intrathecal onasemnogene abeparvovec; Novartis, Cambridge, MA) was associated with significant improvements in motor ability when administered to children with spinal muscular atrophy type 2 (SMA 2). Top-line results of the phase 3 STEER clinical study (NCT05089656) pres
- Parafoveal OCT Scans Show Promise as Biomarker of MS Progressionhttps://practicalneurology.com/news/parafoveal-oct-scans-show-promise-in-assessing-ms-progression/2473798/Anatomical variations of parafoveal retinal layer thickness measured using optical coherence tomography (OCT) were associated with clinical outcomes in individuals with multiple sclerosis (MS) according to study results presented at the Americas Committee for Treatment and Research in Multiple Sc
- Radiprodil Designated a Breakthrough Therapy for GRIN-Related Neurodevelopmental Disorderhttps://practicalneurology.com/news/radiprodil-designated-a-breakthrough-therapy-for-grin-related-neurodevelopmental-disorder/2473793/Radiprodil (GRIN Therapeutics, New York, NY), a selective, potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype SB (NR2B or GluN2B), has been granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) for the treatment of seizures associated wi